Work

Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC)

Year: 2018

Type: article

Abstract: Background: Lorlatinib is a selective, potent, brain-penetrant, third-generation ALK/ROS1 tyrosine kinase inhibitor with robust clinical activity in pts with ALK-positive (ALK+) or ROS1-positive (ROS1+) advanced NSCLC. The phase 1/2 study (NCT01970865) assessed lorlatinib in pts with ALK+ or ROS1+ NSCLC based on prior treatment. Phase 2 efficacy/safety was previously reported. Here, we present PRO results.

Source: Annals of Oncology

DOI: 10.1093/annonc/mdy292.022

Authors: S. Peters, A.T. Shaw, B. Besse, E. Felip, B.J. Solomon, R.A. Soo, A. Bearz, S.M. Gadgee, C.-C. Lin, S. Kao, T. Seto, E.T. Masters, A. Abbattista, J.S. Clancy, H. Thurm, A. Reisman, D.R. Camidge

Institutions: Centre Hospitalier Universitaire Vaudois, Massachusetts General Hospital, Université Paris-Sud, Institut Gustave Roussy, Vall d'Hebron Institute of Oncology, Peter MacCallum Cancer Centre, National University Cancer Institute, Singapore, University of Michigan, The Barbara Ann Karmanos Cancer Institute, National Taiwan University Hospital, Chris O’Brien Lifehouse, National Hospital Organization Kyushu Cancer Center, Pfizer (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $5,080

OpenAlex ID: W2898288792

FWCI: 0.507

Cites:

Cited by: 3

Related to: 10